ISRCTN13323475进行中（未招募）4 期
SWitching InflixiMab to SUbcut from Intravenous Therapy (SWIMSUIT)
niversity Hospital Southampton NHS Foundation Trust0 个研究点目标入组 200 人开始时间: 2021年2月10日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Confirmed diagnosis of Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, and/or ankylosis spondylitis
- •2. Established on IV infliximab (>4 doses) prior to study enrolment
- •3. Anticipated to remain on infliximab for the duration of the study
- •4. Last dose of IV infliximab received <8 weeks ago
- •5. Able to comply with study requirements
- •6. Able to provide informed consent
- •7. Aged =18 years
排除标准
- •1. Allergic to any of the known excipients of infliximab
- •2. Scheduled for a surgical procedure or planned hospitalisation within 6 months of enrolment
- •3. Not anticipated to remain on infliximab for >6 months after enrolment
- •4. Pregnant or lactating
研究者
相似试验
招募中
1 期
Subcutaneous infliximab after a previous intravenous dose optimization (AMARETTO trial)lcerative colitis (UC), Inflammatory bowel disease type unclassified (IBDU) and Crohn's disease (CD)MedDRA version: 20.0Level: PTClassification code: 10011401Term: Crohn's disease Class: 100000004856MedDRA version: 20.1Level: LLTClassification code: 10045365Term: Ulcerative colitis Class: 10017947MedDRA version: 20.1Level: PTClassification code: 10021972Term: Inflammatory bowel disease Class: 100000004856CTIS2023-508166-15-00Belgian IBD Research and Development275
尚未招募
不适用
Switching from intravenous to subcutaneous infliximab in adult patients with inflammatory bowel disease: evaluation of exposure parameters (SHUFFLE-study)Inlammatory bowel disease1001796910003816NL-OMON56467Zuyderland Medisch Centrum36
招募中
不适用
Retreatment with subcutaneous Infliximab in patients with refractory Crohn’s diseaseK50Crohn disease [regional enteritis]DRKS00030670niversitätsklinikum Freiburg30
进行中（未招募）
不适用
Intra-articular and intravenous infliximab in the treatment of resistant seronegative oligoarthritis of the knee - Seronegative Oligoarthritis of the Knee StudyEUCTR2009-015810-23-GBniversity of Leeds30
已完成
2 期
A study of infliximab administration method for tacrolimus-resistant active ulcerative colitisulcerative colitisJPRN-UMIN000013716Yokohama City University Medical Center40